MedPath

Evaluation of the Changes in HIV-1 Burden in Peripheral Blood and Lymphoid Tissue Following Zidovudine ( AZT ) Treatment in HIV-1-Infected Patients With CD4+ Cells Between 100 and 500 Cells/mm3.

Phase 1
Completed
Conditions
HIV Infections
Registration Number
NCT00000818
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Brief Summary

PRIMARY: To determine the effect of 8 weeks of zidovudine (AZT) treatment on the HIV-1 burden in peripheral blood and lymphoid tissue in HIV-1-infected, AZT-naive patients with CD4+ T lymphocyte counts between 100 and 500 cells/mm3.

SECONDARY: To determine the extent to which apoptosis (programmed cell death) occurs in these patients.

In previous trials of AZT treatment in HIV-infected patients, an antiviral effect has been clearly demonstrated by quantitative measurement of virus in plasma and peripheral blood mononuclear cells. However, the lymphoid tissues appear to be a major reservoir for HIV-1 and a major site of virus replication in HIV-infected persons. Further data is needed to assess the effect of treatment on viral burden and HIV-1 replication in lymphoid tissue.

Detailed Description

In previous trials of AZT treatment in HIV-infected patients, an antiviral effect has been clearly demonstrated by quantitative measurement of virus in plasma and peripheral blood mononuclear cells. However, the lymphoid tissues appear to be a major reservoir for HIV-1 and a major site of virus replication in HIV-infected persons. Further data is needed to assess the effect of treatment on viral burden and HIV-1 replication in lymphoid tissue.

Patients receive AZT daily for 8 weeks and are followed in clinic at weeks 2, 4, 6, 8, 9, and 14 (or possibly via telephone call at week 14). Patients undergo a lymph node biopsy at day 0 and week 8.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
18
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (9)

Cedars Sinai Med Ctr

πŸ‡ΊπŸ‡Έ

Los Angeles, California, United States

Palo Alto Veterans Affairs Health Care System

πŸ‡ΊπŸ‡Έ

Palo Alto, California, United States

AIDS Community Research Consortium

πŸ‡ΊπŸ‡Έ

Redwood City, California, United States

Mount Zion Med Ctr / UCSF

πŸ‡ΊπŸ‡Έ

San Francisco, California, United States

North Broward Hosp District

πŸ‡ΊπŸ‡Έ

Fort Lauderdale, Florida, United States

Goodgame Med Group

πŸ‡ΊπŸ‡Έ

Maitland, Florida, United States

Univ of Illinois

πŸ‡ΊπŸ‡Έ

Chicago, Illinois, United States

Univ of Texas Southwestern Med Ctr of Dallas

πŸ‡ΊπŸ‡Έ

Dallas, Texas, United States

Baylor College of Medicine / Houston Veterans Adm Med Ctr

πŸ‡ΊπŸ‡Έ

Houston, Texas, United States

Cedars Sinai Med Ctr
πŸ‡ΊπŸ‡ΈLos Angeles, California, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

Β© 2025 MedPath, Inc. All rights reserved.